LAUSR

People around the globe rely on their blood samples for their glucose level measurement. There is a demand for non-invasive, precise and cost-effective solutions to monitor blood glucose level and control of diabetes. Serum glucose is an accurate blood glucose measurement method in comparison to capillary glucose measurement. Presently, the serum glucose is measured through laboratory setup with an invasive approach. The invasive method is painful and is not suitable for continuous glucose measurement. In this paper, we propose a novel wearable non-invasive consumer device (called iGLU 2.0) which can be used by consumers for accurate continuous blood glucose monitoring. This device uses a novel short near infrared (NIR) spectroscopy developed by us. It is incorporated with Internet-of-Medical-Things (IoMT) for smart healthcare where the healthcare data is stored on the cloud and is accessible to the users and caregivers. Analysis of the optimized regression model is performed and the system is calibrated and validated through healthy, prediabetic and diabetic patients. The robust regression models of serum glucose level is then deployed as the mechanism for precise measurement in iGLU 2.0. The performance of iGLU 2.0 is validated with the prediction of capillary blood glucose using Average Error (AvgE) and Mean Absolute Relative Difference (mARD) which are calculated as 6.09% and 6.07%, respectively, whereas for serum glucose, AvgE and mARD are estimated as 4.88% and 4.86%, respectively.